4DMT to Present at the 44th Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
4D Molecular Therapeutics (NASDAQ: FDMT) will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, Jan 14, 2026. The presentation is scheduled for 7:30 a.m. PT and will be available via webcast.
Members of 4DMT management will be available for one-on-one meetings. An archived copy of the webcast will be available for up to one year in the company’s Investors events section at the investor website.
Positive
- None.
Negative
- None.
News Market Reaction 6 Alerts
On the day this news was published, FDMT gained 3.55%, reflecting a moderate positive market reaction. Our momentum scanner triggered 6 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $22M to the company's valuation, bringing the market cap to $651M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus 1 Up
Peers show mixed moves: MBX up 6.64% while DSGN, OCGN, LRMR and TECX are modestly down, indicating no clear sector-wide biotech trend tied to this conference-related headline.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Nov 20 | Conference participation | Neutral | -4.3% | Announced Evercore Healthcare Conference fireside chat and webcast access. |
| Nov 17 | Management change | Positive | +1.5% | Appointed new CFO to lead finance and strategic initiatives. |
| Nov 14 | Equity compensation | Neutral | +1.5% | Granted 45,400 RSUs to new hires under inducement plan. |
| Nov 10 | Earnings and updates | Neutral | -3.1% | Reported Q3 2025 results plus Otsuka deal and cash position. |
| Nov 06 | Conference participation | Neutral | -3.9% | Announced Jefferies London conference appearance and webcast. |
Recent conference and corporate updates often coincided with modest single-day declines despite largely neutral-to-positive content.
Over the past month, FDMT has highlighted conferences, financing, and strategic progress. On Nov 6–10, 2025, it reported positive PRISM Phase 1/2 wet AMD data, a collaboration with Otsuka including an $85 million upfront payment, and Q3 2025 results with $372.2 million cash plus an underwritten equity offering. Subsequent news covered Jefferies and Evercore conferences and a new CFO. Today’s J.P. Morgan conference presentation continues this pattern of visibility-focused updates rather than new clinical or financial data.
Market Pulse Summary
This announcement highlights 4DMT’s participation in the 44th Annual J.P. Morgan Healthcare Conference on Jan 14, 2026, with a 7:30 a.m. PT presentation and a webcast archived for up to one year. It continues a series of visibility events following recent conferences, a major Otsuka collaboration, and an underwritten equity offering. Investors may focus on how management frames cash runway, late-stage ophthalmology programs, and upcoming milestones discussed during the presentation.
AI-generated analysis. Not financial advice.
EMERYVILLE, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that the Company will present at the 44th Annual J.P. Morgan Healthcare Conference. Members of the management team will also be available for one-on-one meetings.
44th Annual J.P. Morgan Healthcare Conference
| Presentation Date: | Wednesday, Jan 14, 2026 |
| Presentation Time: | 7:30 a.m. PT |
| Webcast Link: | Webcast |
An archived copy of the webcast will be available for up to one year on the “Investors” section of the 4DMT website at https://ir.4dmoleculartherapeutics.com/events.
About 4DMT
4DMT is a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. The Company’s lead product candidate 4D-150 is designed to be a backbone therapy forming the foundation of treatment of blinding retinal vascular diseases by providing multi-year sustained delivery of anti-VEGF (aflibercept and anti-VEGF-C) with a single, safe, intravitreal injection, which substantially reduces the treatment burden associated with current bolus injections. The Company’s lead indication for 4D-150 is wet age-related macular degeneration, which is currently in Phase 3 development, and second indication is diabetic macular edema. The Company’s second product candidate is 4D-710, which is the first known genetic medicine to demonstrate successful delivery and expression of the CFTR transgene in the lungs of people with cystic fibrosis after aerosol delivery. 4D Molecular Therapeutics™, 4DMT™, Therapeutic Vector Evolution™, and the 4DMT logo are trademarks of 4DMT.
All of the Company’s product candidates are in clinical or preclinical development and have not yet been approved for marketing by the U.S. Food and Drug Administration or any other regulatory authority. No representation is made as to the safety or effectiveness of the Company’s product candidates for the therapeutic uses for which they are being studied.
Learn more at www.4DMT.com and follow us on LinkedIn.
Contacts:
Media:
Jenn Gordon
dna Communications
Media@4DMT.com
Investors:
Julian Pei
Head of Investor Relations and Strategic Finance
Investor.Relations@4DMT.com
FAQ
When will 4D Molecular Therapeutics (FDMT) present at the J.P. Morgan Healthcare Conference?
How can investors watch the 4D Molecular Therapeutics (FDMT) presentation on Jan 14, 2026?
Where will the archived 4D Molecular Therapeutics (FDMT) webcast be hosted after the Jan 14, 2026 presentation?
Will 4D Molecular Therapeutics (FDMT) management be available for meetings at the Jan 2026 J.P. Morgan conference?
What time zone is the 4D Molecular Therapeutics (FDMT) presentation time listed in?
